[Retinal diseases].
Larricart
P
P
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000962:Antimalarials / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D016644:Canthaxanthin; D002338:Carotenoids / Q000009:adverse effects / Q000031:analogs & derivatives; D002738:Chloroquine / Q000009:adverse effects; D003276:Contraceptives, Oral / Q000009:adverse effects; D003676:Deferoxamine / Q000009:adverse effects; D004071:Digitalis Glycosides / Q000009:adverse effects; D004837:Epinephrine / Q000009:adverse effects; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects; D008266:Macula Lutea / Q000187:drug effects; D008916:Miotics / Q000009:adverse effects; D010640:Phenothiazines; D011803:Quinine / Q000009:adverse effects; D012164:Retinal Diseases / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D003276:Contraceptives, Oral; D004071:Digitalis Glycosides; D008916:Miotics; D010640:Phenothiazines; D002338:Carotenoids; D016644:Canthaxanthin; D002738:Chloroquine; D011803:Quinine; D003676:Deferoxamine; D007213:Indomethacin; D004837:Epinephrine
Les affections rétiniennes.